143 results on '"Riggs, Michael W."'
Search Results
2. A symbiotic bacterium of shipworms produces a compound with broad spectrum anti-apicomplexan activity
3. Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned
4. Genomic and virulence analysis of in vitro cultured Cryptosporidium parvum
5. Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection
6. Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy
7. Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis
8. Association of IL-10 Expression by Mucosal Lymphocytes with Increased Expression of Cryptosporidium parvum Epitopes in Infected Epithelium
9. Calf Clinical Model of Cryptosporidiosis for Efficacy Evaluation of Therapeutics
10. Modelling Cryptosporidium infection in human small intestinal and lung organoids
11. Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis
12. Cryptosporidiosis in Cats, Dogs, Ferrets, Raccoons, Opossums, Rabbits, and Non-Human Primates
13. Competing Values in the Culinary Arts and Hospitality Industry: Leadership Roles and Managerial Competencies
14. Glyoxalase 1 as a Novel Molecular Marker of High-Grade Prostatic Intraepithelial Neoplasia and Causative Effector in the Progression of Prostate Cancer
15. Antibody fusions reduce onset of experimental Cryptosporidium parvum infection in calves
16. PHOSPHOLIPASES AND CATIONIC PEPTIDES INHIBIT CRYPTOSPORIDIUM PARVUM SPOROZOITE INFECTIVITY BY PARASITICIDAL AND NON-PARASITICIDAL MECHANISMS
17. Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis
18. Gossypiboma-induced abdominal fibrosarcoma in a German shepherd
19. A symbiotic bacterium of shipworms produces a compound with broad spectrum anti-apicomplexan activity.
20. One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases
21. Neonatal Mouse Gut Metabolites Influence Cryptosporidium parvum Infection in Intestinal Epithelial Cells
22. Gut metabolites influence susceptibility of neonatal mice to cryptosporidiosis
23. Modelling Cryptosporidium infection in human small intestinal and lung organoids
24. Novel Virulence Strategies of Enteropathogenic Escherichia Coli: An Integrated Study
25. Extended-spectrum antiprotozoal bumped kinase inhibitors: A review
26. 5-Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of Cryptosporidium parvum
27. The Secreted Effector Protein EspZ Is Essential for Virulence of Rabbit Enteropathogenic Escherichia coli
28. Selective and Combined Immunodeficiencies in Horses1
29. Studies on Two Genomic Variants of Taura Syndrome Virus: Infection under Hyperthermic Conditions and Detection with a Novel Monoclonal Antibody
30. Cathelicidin-like Helminth Defence Molecules (HDMs): Absence of Cytotoxic, Anti-microbial and Anti-protozoan Activities Imply a Specific Adaptation to Immune Modulation
31. Taura Syndrome Virus (TSV) of Penaeid Shrimp: Infection of Penaeus monodon, Resistance of Litopenaeus vannamei and Ultrastructure of the Replication Site in Infected Cells
32. The Role of the Left Temporal Lobe in Naming and Semantic Knowledge
33. Antibodies Fused to Innate Immune Molecules Reduce Initiation of Cryptosporidium parvum Infection in Mice
34. Cryptosporidiosis in Neonatal Calves
35. Antigenic differences within the Cryptosporidium hominis and Cryptosporidium parvum surface proteins P23 and GP900 defined by monoclonal antibody reactivity
36. Characterization of a Low Molecular Weight Glycolipid Antigen from Cryptosporidium parvum
37. Recent advances in cryptosporidiosis: the immune response
38. Efficacy of Monoclonal Antibodies against Defined Antigens for Passive Immunotherapy of Chronic Gastrointestinal Cryptosporidiosis
39. Targeted Disruption of CSL Ligand ‐ Host Cell Receptor Interaction in Treatment of Cryptosporidium parvum Infection
40. Characterization of an Intestinal Epithelial Cell Receptor Recognized by theCryptosporidium parvumSporozoite Ligand CSL
41. Characterization and Formulation of Multiple Epitope-Specific Neutralizing Monoclonal Antibodies for Passive Immunization against Cryptosporidiosis
42. Cryptosporidium parvum Apical Complex Glycoprotein CSL Contains a Sporozoite Ligand for Intestinal Epithelial Cells
43. Evidence of Thymus-Independent Local and Systemic Antibody Responses to Cryptosporidium parvum Infection in Nude Mice
44. Cryptosporidium parvum Sporozoite Pellicle Antigen Recognized by a Neutralizing Monoclonal Antibody Is a β-Mannosylated Glycolipid
45. Role of Immunoglobulin A Monoclonal Antibodies against P23 in Controlling Murine Cryptosporidium parvum Infection
46. A cloned gene of Cryptosporidium parvum encodes neutralization-sensitive epitopes
47. Protective Monoclonal Antibodies Define a Distinct, Conserved Epitope on an Apical Complex Exoantigen of Cryptosporidium parvum Sporozoites
48. Neutralizing Monoclonal Antibody Protects Against Cryptosporidium parvum Infection by Inhibiting Sporozoite Attachment and Invasion
49. Neuroaxonal Degeneration in Sheep GrazingSorghumPastures
50. Suspected ciliary dysfunction in Chinese Shar Pei pups with pneumonia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.